This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs
by Zacks Equity Research
Alvotech shares surge after the company resubmits FDA applications for its biosimilar candidates, AVT05 and AVT06, with reviews expected within six months.
TEVANegative Net Change IMCRNegative Net Change ALVOPositive Net Change INDVNegative Net Change
biotechs
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
by Zacks Equity Research
Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.
NVSNegative Net Change BIIBNegative Net Change RHHBYNegative Net Change IONSNegative Net Change
biotechs
Why Health Care's Seasonal Tailwind Looks Especially Compelling This Year
by Bryan Hayes
The seasonal strength lines up with major medical and scientific conferences that cluster during this period.
MRKNegative Net Change LLYPositive Net Change
biotechnology biotechs earnings interest-rate investing medical oncology-screening pharmaceuticals smart-health
4 Biotech Stocks Investors Should Watch in 2026
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.
LQDAPositive Net Change STOKNegative Net Change IMNMPositive Net Change IMCRNegative Net Change
biotechnology biotechs cancer medical pharmaceuticals
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s?
by Ahan Chakraborty
LLY's 2026 deal-making spree spans vaccines, oncology and neuroscience, aiming to diversify growth beyond GLP-1s amid rising obesity competition.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
by Zacks Equity Research
Regeneron expands its CytomX partnership to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion.
REGNNegative Net Change BMYNegative Net Change MRKNegative Net Change CTMXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know
by Zacks Equity Research
KOD surges on positive phase III Zenkuda data, accelerated regulatory plans, advancing late-stage programs and a strengthened balance sheet.
LQDAPositive Net Change KODNegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechs
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
by Zacks Equity Research
Rezolute rises 38% in a week after interim upLIFT data shows most tumor HI patients cut or eliminate IV glucose support.
RZLTNegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechs medical
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
by Zacks Equity Research
Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.
BMYNegative Net Change GILDNegative Net Change RCUSPositive Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Alnylam Bets on AI for Speedy RNAi Drug Discovery and Development
by Zacks Equity Research
ALNY teams up with Inceptive in a deal worth up to $2B, using AI models and proprietary RNAi data to speed drug discovery and improve candidate selection.
ALNYNegative Net Change LQDAPositive Net Change IMCRNegative Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals